16 March 2007
Results of liver transplantation for hepatocellular cancer
Krzysztof Zieniewicz, Waldemar Patkowski, Paweł Nyckowski, Abdulsalam Alsharabi, Bogdan Michałowicz, Jacek Pawlak, Rafał Paluszkiewicz, Tadeusz Wróblewski, Bogusław Najnigier, Piotr Smoter, Piotr Hevelke, Anna Skwarek, Piotr Remiszewski, Marcin Kotulski, Michał Skalski, Leszek Pączek, Marek KrawczykAnn Transplant 2007; 12(1): 11-14 :: ID: 495357
Abstract
Background: Liver transplantation (LTx) for hepatocellular carcinoma (HCC) in cirrhotic liver is nowadays generally accepted treatment modality.
Aim of Study: Overview of the indications and results of the LTx in the patients with HCC, the first one performed in 2001.
Material/Methods: Among 357 adult liver transplant recipients in the period 1994–04.2005, in 26 (7%) the indication was HCC (16 men: 10 women, age 20–65, mean 46.5 years). HCC developed in cirrhotic liver in 25 pts. 12 (48%) were Child C, 10 (30%) – Child B and 3 (12%) – Child A patients. As underlying disease in 2 patients (8%) was alcoholic cirrhosis, in 7 (28%) – HBV cirrhosis, in 12 (48%) – HCV cirrhosis and in 4 (16%) – HBV/HCV cirrhosis. Milano criteria were met in 20 patients (77%). The mean waiting list time was 2.9 months (range 1–6 months). Seven patients underwent liver resection and 1 transarterial chemoembolization prior to LTx. 11 patients (42%) were operated on with use of veno-venous bypass, in 15 patients (58%) the piggy back technique was applied. Rapamycine based immunosuppression was preferred in post-LTx treatment.
Results: Operative mortality was 0. 4 patients required relaparotomy for intraperitoneal bleeding. 21 patients (81%) are alive in good general condition, 19 – free of the disease. 5 patients died 7–28 months after LTx (mean 16.7). The mean survival time is 20 months (range 1–38).
Conclusions: Liver transplantation is safe and effective method of treatment of the selected patients with HCC in cirrhotic liver. Further investigations concerning the precise indications, timing of the transplantation and adjuvant treatment are necessary.
Keywords: liver transplantation (LTX), Hepatocellular carcinoma (HCC)
In Press
Original article
Adipose Tissue Can Have a Protective Effect on Outcome After Simultaneous Pancreas–Kidney Transplantation i...Ann Transplant In Press; DOI: 10.12659/AOT.944518
Original article
Preoperative Evidence-Based Practice for Prevention of Early Postoperative Infections in Patients Receiving...Ann Transplant In Press; DOI: 10.12659/AOT.943610
Original article
Prediction of Renal Graft Function 1 Year After Adult Deceased-Donor Kidney Transplantation Using Variables...Ann Transplant In Press; DOI: 10.12659/AOT.944603
Original article
Impact of Donor-Recipient Relationship on Long-Term Outcomes in Living-Related Donor Kidney TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.945065
Most Viewed Current Articles
05 Apr 2022 : Original article 12,804
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 9,760
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,192
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,007
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860